The wheels are coming off the generic solution. With manufacturing resources scarce, the owners of the businesses just pull production of meds that patients have taken for years but are relatively unprofitable. When the demand is sufficient for the desired price rise to occur, they reappear. It’s a good business model, heh?
Not to mention that the Gx manufacturers don’t do research. They employ lawyers, not researchers.
The Gx business model is no different from that of commodity chemicals.